The influenza A virus is a causative agent of influenza, which infects human cells and uses host factors to accomplish viral genome replication as part of its life cycle. The nucleoprotein (NP) and PB2 of the influenza virus associate with importin a1 to gain access to the host nucleus through a ternary import complex. Killer cell-mediated cytotoxicity is the primary mechanism of eliminating the influenza virus. Here, we showed that lymphokine-activated killer cells participated in the elimination of the influenza virus. Granzyme (Gzm) K inhibition elevated viral replication in vitro and aggravated viral infection in vivo. We identified that importin a1 and its transport partner protein importin b are physiological substrates of GzmK. Proteolysis of these two substrates wrecked their association to generate the importin a1/b dimer and disrupted transportation of viral NP to the nucleus, leading to inhibition of influenza virus replication.
Influenza A virus is a causative agent of influenza, a disease that results in devastating pandemics and global panic. The influenza A virus is a negative-strand RNA virus containing eight segments of RNA as its genome. Transcription and replication of the viral genome are fulfilled in a host nucleus through RNAdependent RNA polymerase, which has three subunits, namely PB1, PB2, and PA. The nucleoprotein (NP) associates with viral RNAs (vRNA) to form a viral ribonucleoprotein (vRNP) complex to assist the polymerase in replicating the viral genome. It has been reported that the different subunits of RNA polymerase bind an importin a/b dimer or an importin b homolog receptor of host cellular factors to gain access to the nucleus of the infected host cell for viral replication. 1 Moreover, NP can also bind to importin a1 to enter the nucleus. 2 Killer lymphocytes eliminate both viruses and cancer cells through granule-mediated cytotoxicity. 3, 4 These lymphocytes undergo exocytosis, releasing cytotoxic granules that release cytotoxic elements such as the pore-forming protein (PFP) perforin and granzymes (Gzms), which are taken up into the target cell by endocytosis. PFP actually helps Gzms enter the target cell, where they trigger apoptosis. 5 Topham et al. 6 reported that killer cell-mediated cytotoxicity is a primary mechanism of eliminating the influenza virus. More recently, Regner et al. 7 reported that gzmA Â B double deficiency (gzmAB À/À ) does not cause any impairment of infected target cell clearance. This suggests that other Gzms may participate in pathogenic elimination. Jenkins et al. 8 revealed that CTLs of gzmAB À/À mice, which expressed only GzmK and very limited quantities of GzmC, showed similar viral clearance capacity as did wild-type (WT) controls. This indicates that GzmK has a critical role in the elimination of the influenza virus. However, how GzmK inhibits viral replication remains unclear.
GzmK is the alternate tryptase among all Gzms, linking closely with the tryptase GzmA on the same chromosome in humans and mice. GzmK is expressed to a great degree in CD56 bright natural killer (NK) cells, CD3 þ CD8 þ and CD4 þ cytotoxic T cells, and gdT cells. 9 We have previously demonstrated that GzmK targets the SET complex to initiate caspase-independent cell death. 10, 11 GzmK can induce the rapid generation of reactive oxygen species through a Biddependent pathway. 12 GzmK also cleaves the valosincontaining protein (VCP) to destroy the ER-associated degradation (ERAD) pathway, resulting in an ER stress of the target cell. 13 We also found that GzmK proteolyzes the tumor suppressor p53 to generate three pro-apoptotic segments that potentially increase elimination of target tumor cells. 14 In this study, we showed that GzmK can cleave the importin a1/b dimer and disrupt transportation of viral NP to the nucleus, resulting in elimination of influenza virus in vivo.
Results

GzmK blockade aggravates influenza virus infection.
Harari et al. 15 demonstrated that influenza A virus-specific CD8 þ T cells possess a profile of perforin
þ , CTL cells of gzmAB À/À mice, which express only GzmK and very limited amounts of GzmC, exhibited effective clearance of influenza virus. 8 These reports suggest that GzmK has a critical role in the host's defense against influenza virus infection. To determine the role of GzmK in the elimination of influenza virus in vivo, Balb/c mice (4-6-weeks old) were intravenously injected with GzmK-specific inhibitor (KI) to inhibit endogenous GzmK before viral challenge. We have previously showed that the GzmK inhibitor Ac-YRFK-CMK can specifically block enzymatic activity of GzmK. 13 Mice were then intranasally infected with the Flu A/WSN/33 (H1N1) (10 2 PFU/mouse) virus. KI-pretreated mice showed significantly higher viral loads in their lungs than did PBS controls at both 3 days and 6 days post infection (p.i.) (Figure 1a) . At 3 d.p.i., viruspositive cells were found mainly in the bronchial epithelium in PBS control mice, whereas mice treated with the GzmK inhibitor also showed infected regions in alveolar epithelial cells around the bronchia (Figure 1b) . At 6 d.p.i., infections of PBS control mice appeared to be restricted to the alveolar epithelium and showed much weaker viral protein staining intensity relative to KI-pretreated mice. In contrast, KI-pretreated mice showed heavy staining on most bronchial cells ( Figure 1b) . We further confirmed the above findings through detection of the intensity of vRNA in infected cells through in situ hybridization assay. Lung sections of 6 d.p.i. mice were detected for vRNA for the M2 protein. KI-pretreated mice showed more viral RNA-hybridized cells and more hybrid points in infected cells than did PBS control mice (Figure 1c ). These results indicate that GzmK has a critical role in the elimination of influenza A virus.
Attenuation of LAK cell-mediated clearance of influenza virus by GzmK inhibition. We further explored whether lymphokine-activated killer (LAK) cells participate in clearance of the influenza virus. LAK cells were obtained from PBMC cells (healthy donors) with IL-2 (1000 Units/ml) stimulation. We used a luciferase reporter system to detect the replication of influenza A virus as described previously. 16 The reporter plasmid pPolINSluc was transfected into human alveolar epithelial cell line A549 cells 12 h before infection along with an intrinsic control plasmid pRL-SV40. The above treated cells were then infected with Flu A/WSN/33 (H1N1) and incubated with LAK cells with or without KI at an E/T ratio of 1 : 1 for 24 h. Viral replication in infected cells was analyzed through a dual luciferase assay. Infected A549 cells were all alive at this point in time (data not shown). LAK cells repressed influenza virus replication by 53.4% (Figure 2a) . In contrast, LAK cells with GzmK inhibition elevated replication over 49.0% relative to LAK cell-treated target cells. To further verify the inhibitory role of GzmK in influenza virus replication, we simplified the factors for influenza virus replication, assuming that only viral polymerase and NP protein (Pol þ NP) were necessary for vRNA amplification. The reporter system and experimental procedure were the same as those used for cells infected with Flu A/WSN/33 (H1N1). As expected, LAK cells significantly inhibited the replication of vRNA by 81.7%, whereas LAK cells with GzmK inhibition rescued repression by 59.0% (Figure 2b ). GzmK associates with importin a1. An inactive GzmK mutant (S-AGzmK) was immobilized with Affi-Gel10 resin and passed through K562 cell lysates for affinity chromatography. The S-AGzmK column was eluted with NaCl concentration gradients. After elution with 500 mM NaCl, the eluted fractions were resolved on SDS-PAGE, followed by silver staining (Figure 3a) . The six major bands were eluted and cut out for mass spectrometry. These proteins were identified as VCP, importin a1, tubulin b, OLA1, SET, and pp32. We have previously demonstrated that VCP and SET are physiological substrates of GzmK and that pp32 associates with GzmK in the SET complex. 10, 11 Interestingly, tubulin b was also identified as a physiological substrate of GzmK by the Bovenschen et al. 17 OLA1 is a kind of ATPase that was reported to suppress cellular antioxidant response. 18 Importin a1, a member of the karyopherin a family, acts as a component of the nuclear transport complex to transport protein cargos between the cytoplasm and the nucleus. 19 Intriguingly, host cell importin a1 was reported to bind the NP and PB2 of influenza A virus and to import them into the nucleus for replication of the viral genome. 2, 20 We next decided to determine whether GzmK would associate with importin a1 under physiological conditions. S-AGzmK could precipitate native importin a1 in K562 cell lysates (Figure 3b ). Importin a1 also precipitated S-AGzmK from S-AGzmK-incubated lysates. Similar results were obtained using HeLa cell lysates (data not shown). IgG used as a control did not pull down either importin a1 or S-AGzmK. To confirm the direct interaction of GzmK with importin a1, recombinant importin a1 (rImpa1) was incubated with S-AGzmK for co-immunoprecipitation assay. S-AGzmK co-precipitated rImpa1 and vice versa (Figure 3c ), whereas control IgG and rGST had no effect. Therefore, it was concluded that S-AGzmK binds directly to importin a1 in its recombinant and native forms.
Importin a1 is a physiological substrate of GzmK. To determine whether importin a1 is cleaved by GzmK, rImpa1 (0.5 mM) was incubated with different concentrations of Figure 3 GzmK associates with Importin a1. (a) Importin a1 (Impa1) was eluted with the SET complex. The eluted bands were identified by mass spectrometry. (b) GzmK interacts with native importin a1. In all, 10 mg S-AGzmK was incubated with K562 cell lysates followed by co-immunoprecipitation with anti-GzmK antibody (left panel) or antiimportin a1 mAb (right). (c) GzmK binds directly to recombinant importin a1 (rImpa1). In all, 10 mg S-AGzmK and 10 mg rImpa1 were incubated and co-immunoprecipitation assay was performed as described above. IgG served as a negative antibody control, and rGST was used as a negative protein control. IP: immunoprecipitation À2 for 2 h. The infected A549 cells were incubated with IL-2-activated LAK cells at an E/T ratio of 1 : 1 followed by luciferase assay. For GzmK inhibition, LAK cells were pretreated with KI for 2 h. **Po0.001. (b) GzmK inhibition facilitates LAK cell-mediated replication of the influenza virus. A549 cells were transfected with influenza A polymerase (PB1, PB2, and PA) and NP plasmids (Pol þ NP), the luciferase plasmid pPolI-NS-luc, and the control plasmid pRL-SV40, followed by the above assay. ***Po0.0001
GzmK at 371C for 1 h or with 0.5 mM GzmK for 5-60 min. rImpa1 began to be degraded at a low concentration of 60 nM GzmK ( Figure 4a , left panel). rImpa1 was completely processed at 0.25 mM GzmK. By 5 min, rImpa1 began to be proteolyzed and was completely processed after 30 min (Figure 4a , right panel). rImpa1 was not cleaved by S-AGzmK. Thus, it was concluded that rImpa1 degradation requires the enzymatic activity of GzmK. We further identified the cleavage site by using site-directed mutagenesis. The Arg13Ala mutant (R13A-Impa1) was not cleaved by GzmK (Figure 4b ). Therefore, GzmK cleaved importin a1 after Arg 13 at the N terminus to generate a truncated form (tImpa1).
To further confirm that GzmK cleaves native importin a1 in mammalian cells, K562 cell lysates (2 Â 10 5 equivalent) were incubated with different concentrations of GzmK at 371C for 60 min. Native importin a1 in cell lysates was degraded by GzmK in a dose-dependent manner, whereas the inactive S-AGzmK exerted no effect ( Figure 4c , left panel). The SET protein, a substrate of GzmK, served as a positive cleavage control and b-actin served as a negative control. Moreover, Impa1 began to be cleaved by GzmK by 10 min in a timedependent manner (Figure 4c , right panel). To further confirm that importin a1 processing is physiologically relevant, K562 cells were treated with different concentrations of GzmK for 3 h or with 1 mM GzmK for 1-3 h in the presence of replicationdeficient adenovirus type V (Ad). As expected, importin a1 of target cells was cleaved in a dose-and time-dependent manner (Figure 4d ). GzmK and Ad alone or S-AGzmK plus Ad were not able to degrade importin a1. SET cleavage also served as a positive control and b-actin remained unchangeable as a good loading control. Similar results were found using HeLa cells (data not shown).
GzmK inhibition blocks degradation of importin a1 in LAK cell-mediated cytolysis. We further determined whether GzmK could cause degradation of importin a1 in LAK cell-mediated cytotoxicity. The Impa1-Myc protein was overexpressed in K562 cells using an MSCV-IRES-GFP retroviral system. Positive cells expressing Impa1-Myc were sorted by a GFP marker through an FACS sorter. K562 cells 5 Jurkat cells were incubated with different doses of GzmK for 3 h or with 1 mM GzmK for the indicated times at 371C in the presence of replication-deficient adenovirus type V (Ad) (100 PFU/ml). SET was used as a positive control. b-Actin remained unchanged as a loading control. (e and f) GzmK degrades importin a1 in LAK cell-mediated cytolysis. K562 cells expressing Impa1-Myc were incubated with IL-2-activated LAK cells at the indicated E/T ratios followed by immunoblotting. The GzmK known substrate Bid was detected as a positive control. GFP was expressed in K562 cells and visualized as a loading control (panel e). Importin a1 was visualized with anti-Myc antibody (red) using the immunofluorescence assay (panel f). Nuclei were stained with DAPI (blue). DIC: differential interference contrast. The color reproduction of this figure is available at the Cell Death and Differentiation journal online with the Impa1-Myc expression were incubated with IL-2-activated LAK cells at E/T ratios of 5 : 1 and 10 : 1 followed by immunoblotting. For GzmK inhibition, LAK cells were pretreated with the GzmK inhibitor. Importin a1 was degraded at an E/T ratio of 5 : 1 and almost proteolyzed at an E/T ratio of 10 : 1 (Figure 4e) . Remarkably, the GzmK inhibitor inhibited degradation of importin a1 at both E/T ratios. Bid was probed as a positive control and GFP served as a target cell loading control. These results were also confirmed by confocal microscopy (Figure 4f 
GzmK also degrades the other transport partner importin b. In the classical nuclear import pathway, importin a1 first recognizes its cytoplasmic cargos by their classical nuclear localization sequences (NLSs), and then associates with importin b (karyopherin b1) to form a ternary import complex for transportation. 21 In this manner, importin b acts as a transport partner for importin a1. We decided to look at whether GzmK could degrade importin b in host cells. Recombinant importin b (rImpb) (0.5 mM) was incubated with different doses of GzmK. rImpb began to be cleaved at a very low concentration of 10 nM GzmK and was completely processed at 0.2 mM GzmK in a dose-dependent manner (Figure 5a, left panel) . GzmK also proteolyzed rImpb in a time-dependent manner (Figure 5a, right panel) . Inactive S-AGzmK had no effect. The cleavage site was identified at Arg 710 of the C terminus through site-directed mutagenesis (Figure 5b (Figure 5c ). The GzmK substrate SET served as a positive control and b-actin was used as a negative control. S-AGzmK displayed no effect. Moreover, importin b was degraded in GzmK-loaded intact K562 cells (Figure 5d ). Meanwhile, importin a1 and SET were Jurkat cells were incubated with 1 mM GzmK and Ad (100 PFU/ml) for 3 h at 371C and probed for importin b, importin a1, SET, and b-actin. (e and f) GzmK cuts importin b during the LAK cellmediated killing process. K562 cells expressing FLAG-Impb were incubated with IL-2-activated LAK cells at the indicated E/T ratios followed by immunoblotting. GFP was specifically expressed in K562 cells and visualized as a loading control (panel e). Importin b was probed with anti-FLAG mAb (red) using immunofluorescence assay (panel f). Nuclei were stained with DAPI (blue). DIC: differential interference contrast. The color reproduction of this figure is available at the Cell Death and Differentiation journal online probed as positive controls. b-Actin was unchanged as a good loading control.
We next detected degradation of importin b in LAK cellattacked target cells. FLAG-Impb-expressing K562 cells were incubated with IL-2-activated LAK cells at E/T ratios of 5 : 1 and 10 : 1. We found that importin b was degraded at both E/T ratios (Figure 5e ). GzmK inhibition suppressed the degradation of importin b. Similar results were confirmed by confocal assay (Figure 5f ). Within 30 min, FLAG-tagged importin b was almost degraded by LAK cells, whereas this degradation could be impeded by the GzmK inhibitor (Figure 5f ). Therefore, importin b is also a physiological substrate for GzmK.
GzmK-truncated importin a1 (tImpa1) and importin b (tImpb) destroy their association. GzmK cleaved importin a1 after Arg 13 in the importin b-binding (IBB) domain that mediates the interaction of importin a1 with importin b (Figure 6a ). Arg 13 is the only strictly conserved residue in the IBB domain of all the importin a homologs, making it critical to interactions with importin b and formation of the transport complex. 22 Thus, we determined whether depletion of the N-terminal moiety of importin a1 by GzmK would impact interactions between importin a1 and importin b. Here, 293 T cells were transiently cotransfected with Myctagged importin a1 (Impa1-Myc) or its GzmK-truncated fragment (tImpa1-Myc) and FLAG-tagged importin b (FLAG-Impb) for 48 h, followed by the co-immunoprecipitation assay. tImpa1-Myc was not precipitated by the anti-FLAG antibody (Figure 6b ), but Impa1-Myc was precipitated as a good interaction control. The anti-FLAG antibody failed to pull down any protein in 293 T cells expressing Impa1-Myc alone. Similarly, 293 T cells were transiently cotransfected with FLAG-tagged importin b (FLAG-Impb) or its GzmK-truncated fragment (FLAGtImpb), as well as Impa1-Myc or tImpa1-Myc for immunoprecipitation. As expected, FLAG-tImpb was not pulled down by the anti-Myc antibody (Figure 6c ), whereas FLAG-Impb was precipitated by this antibody. Notably, tImpa1-Myc and FLAG-tImpb did not interact (Figure 6c) . Similar results were obtained using GST-tagged importin b (GST-Impb) or its GzmK-truncated fragment (GST-tImpb) (Figure 6d ). These results indicate that the interaction between Impa1 and Impb was disrupted after cleavage by GzmK. tImpa1 or tImpb abolishes NP transportation resulting in inhibition of viral replication. As shown above, GzmKtruncated tImpa1 and tImpb lost their ability to interact with their full-length forms. We next tested whether tImpa1 or tImpb could affect transportation of the viral NP protein. First, 293 T cells were cotransfected with the HA-tagged NP (HA-NP) protein and either Impa1-Myc or tImpa1-Myc. We demonstrated that tImpa1 could bind to the NP protein, as did the full-length importin a1 (Figure 7a ). To determine effects of tImpa1 and tImpb on the transportation of NP protein, HeLa cells were precultured for 18 h, penetrated with 40 mg/ml digitonin and then incubated with the Myc-NP protein. Transportation factors for this in vitro transport assay included Ran-GDP and NTF/p10, the indicated combinations of full-length and truncated importin proteins, and an energy regeneration system (ERG). Transport of NP was visualized by immunofluorescence with anti-Myc antibody. Full-length importin a1 and importin b transported the NP protein into the nucleus (Figure 7b ). However, tImpa1 with importin b, tImpb with importin a1, and tImpa1 with tImpb were not. In the above system, we substituted GzmK-treated cell lysates for rImp proteins to obtain similar results (Figure 7c ). GzmK treatment blocked nuclear transportation of the NP protein. As a negative control, it was established that the NP protein would undergo no transportation without ERG.
The NP protein forms the vRNP complex with influenza virus vRNA for viral replication. 23 We supposed that blocking NP transportation might lead to inhibition of viral replication. First, we established a stable 293 T-cell line with importin a1 and importin b double depletion (Figure 7d ). WT 293 T and importin a1 and importin b double-depletion cell lines were cotransfected with plasmids for expression of Pol þ NP and pPolINSluc. pRL-SV40 served as an intrinsic transfection control. Double knockdown of importin a1 and importin b significantly suppressed vRNA polymerase activity (Figure 7d ). To further confirm the effects of importin a1 and importin b on viral replication, we overexpressed full-length importin a1 and importin b, tImpa1 with importin b, tImpb with importin a1, and tImpa1 with tImpb in the 293 T-cell line with double depletion of importin a1 and importin b. Transfection of importin a1 and importin b rescued polymerase activity ( Figure 7e ). As expected, tImpa1 with importin b, tImpb with importin a1, and tImpa1 with tImpb transfection had no effect. These results indicate that truncation of either importin a or importin b disables transport of the NP protein, leading to inhibition of viral replication. 
Discussion
Increasing evidence shows that CD8
þ CTLs have pivotal roles in the control of influenza virus infection through TCRmediated cytotoxicity. 24, 25 However, it takes around a week to prime activation of naive CD8 þ T cells for antigen-driven differentiation and proliferation. These findings imply that NK cells may exert a crucial role in the acute control of virus infection during the early stages. NK cells are considered part of the innate immune system, early attackers of both virusinfected cells and transformed tumor cells. 26, 27 Direct killing and cytokine secretion are the two major effector responses of NK cells. Stimulation of NK cells by viruses can produce cytokines such as IFN-g, GM-CSF, and TNF-a, which cause inflammation, which allows the body to better attack pathogens. NK cells also recognize virus-infected host cells and trigger cell death, resulting in the clearance of infected cells. Interestingly, we found that LAK cells were able to inhibit viral replication and to eliminate the influenza virus.
Although GzmA and GzmB are generally considered to be the most abundant Gzms in humans and mice, 5,28 cytotoxic granules also contain other Gzms that also exert critical functions in the elimination of viruses and tumors. 29 A previous report showed that the level of circulating GzmK was remarkably elevated in virus-infected patients, implying that GzmK has an important role in viral clearance. 30 Jenkins et al. 8 reported that CTLs of gzmA/B À/À mice, which express only GzmK and very limited amounts of GzmC, exhibited effective activity against the influenza virus. Here, we found that in vivo inhibition of GzmK by its specific inhibitor aggravated influenza virus infection. Therefore, Gzms may possess their own specificity with regard to fighting different pathogens.
Like GzmA, GzmK is also a tryptase that induces caspaseindependent cell death. 10 We have previously demonstrated that GzmK targets the GzmA-associated SET complex and cleaves the known substrates of GzmA in that complex, including SET, Ape1, and HMGB2. 10, 11 However, in addition to sharing some substrates with GzmA, GzmK possesses 5 equivalents) were pretreated with 0.5 mM GzmK at 371C for 2 h and then pre-permeabilized HeLa cells with recombinant Myc-NP were added. ERG-absent samples served as negative controls. (d) Double knockdown of Impa1 and Impb decreases the polymerase activity of the influenza virus. 293 T cells were co-transfected with shImpa1 and shImpb plasmids (sh(Impa1 þ Impb)) for 48 h and a stable silenced clone was established. Double-silenced 293 T cells were cotransfected with Flu A Pol þ NP, pPolI-NS-luc, and pRL-SV40, followed by luciferase assay. (e) tImpa1 and tImpb are not able to rescue polymerase activity. Double-silenced 293 T cells were cotransfected with either full-length importin a1 and importin b or their GzmK-truncated fragments, as well as (Pol þ NP) and the luciferase plasmids. ***Po0.0001 its own substrate specificity. GzmK causes mitochondrial damage by cleavage of Bid, which is not degraded by GzmA. 12, 31 GzmK can cleave tumor suppressor p53 at Lys24 and Lys305 to generate three pro-apoptotic fragments, sensitizing tumor cells to GzmK-mediated cytolysis. 14 We determined that VCP is in the SET complex, which is specifically proteolyzed by GzmK to abolish the ERAD pathway, leading to ER stress. 13 In this study, we eluted importin a1 with the known GzmK substrates SET and VCP (VCP is also in the GzmK-associated SET complex) and found that they were cleaved by GzmK, not other Gzms (data not shown). Importin a1 is one member of the importin a family. This family of proteins all have a structurally conserved N-terminal IBB domain that interacts with a transport partner, importin b, to generate a ternary import complex for cytoplasmic cargos bearing a classical NLS. 21, 32 It has been reported that NP and PB2 bind to importin a1 through their NLSs for transport into the host cell nucleus through the importin a1/b dimer. 2, 20 GzmK cleaved importin a1 after Arg 13 in the N-terminal IBB domain, which is crucial to association with importin b. Interestingly, the IBB domains of all human importin a isoforms (importin a1, 3, 4, 5, 6, 7, and 8) are structurally conserved. 33 The N-terminal Arg residue (P1 site) of each isoform is also conserved and the P4-P3-P2-P1 residues are predictively optimal to be cleaved by GzmK 34 (Supplementary Figure 1a) . Notably, we observed that GzmK cleaved all the other importin a isoforms (WT) in addition to importin a1, whereas GzmK did not proteolyze their P1 sitemutated ones (Supplementary Figure 1b) . Moreover, GzmK also degraded importin b at its interaction regions in the C terminus. Thus, GzmK was found to degrade the importin a1/b dimer. These results indicate that GzmK can inhibit the classical importin a/b-mediated nuclear import pathway, which ensures blockade of viral protein import to the host nucleus leading to efficient viral clearance.
Materials and Methods
Cell lines, mice, and viruses. K562 (human erythromyeloblastoid leukemia cell line) cells were maintained in RPMI 1640 medium supplemented with 10% FBS. A549 (human lung adenocarcinoma cell line), MDCK (dog kidney cell line), HeLa (human epithelial carcinoma cell line), and HEK 293 T (human kidney cell line) cells were grown in DMEM supplemented with 10% FBS, 50 mM b-ME, 100 Units/ml penicillin, and 100 mg/ml streptomycin. Balb/c mice 4-6-weeks old were purchased from Vital River Laboratories (VRL, Beijing, China). Recombinant influenza virus Flu A/WSN/33 (H1N1) was rescued from 293 T cells through a reverse genetics system and amplified in MDCK cells. Viral infectivity was titrated using a plaque assay.
Antibodies and reagents. Polyclonal antibodies against GzmK were generated by our laboratory. Commercial antibodies included mouse monoclonal antibody for importin a1 (BD Pharmingen, San Jose, CA, USA), importin b (BD Pharmingen), FLAG (Sigma-Aldrich, St. Louis, MO, USA), c-Myc (Santa Cruz Biotechnology, Santa Cruz, CA, USA), b-actin (Sigma-Aldrich), rabbit polyclonal antibodies for SET (Santa Cruz Biotechnology), c-Myc (GenScript USA Inc., Piscataway, NJ, USA), HRP-conjugated sheep anti-mouse IgG and HRP-conjugated sheep anti-rabbit IgG (Santa Cruz Biotechnology), Alexa 594-conjugated donkey anti-mouse IgG (Molecular Probes, Carlsbad, CA, USA), and Alexa 488-conjugated donkey anti-rabbit IgG (Molecular Probes). Affi-Gel 10 was purchased from Bio-Rad (Hercules, CA, USA). Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA, USA). A dual-luciferase reporter assay system was purchased from Promega (Madison, WI, USA).
Mouse infection. For GzmK inhibition, 100 mg GzmK-specific inhibitor (KI) was intravenously injected into mice the day before infection. PBS was injected into control group mice. Mice were intranasally infected with Flu A/WSN/33 (H1N1) (10 2 PFU/mouse) under parenteral anesthesia. All animals were housed in the institute's P2 mouse facility. Animal care and experiments were performed in accordance with the ethics committee guidelines of the Institute of Biophysics (Chinese Academy of Sciences (CAS), Beijing, China).
IHC and in situ hybridization (ISH) assay. The dissected mouse lungs were fixed with 4% paraformaldehyde, and sectioned for immunohistochemistry (IHC) assay. For in situ hybridization assay, tissue sections were digested with proteinase K for 5 min, and fixed with 4% paraformaldehyde for 3 min. Sections were then treated with 0.25% acetic anhydride for 10 min and pre-hybridized with salmon sperm DNA at 601C overnight, and then hybridized with the denatured digoxigenin-labeled M2 gene cDNA probe (FluA/WSN/33(H1N1)) for 18 h. The sequence of the M cDNA probe was AAGCTTAAGAGGGAGATAACATTCCA TGGGGCCAAAGAAATAGCACTCAGTTATTCTGCTGGTGCACTTGCCAGTTGTA TGGGCCTCATA.
Plasmid construction. Full-length and GzmK-truncated fragments of human importin a1 were amplified from pcDNA3-FLAG-Impa1 (kindly gifted by Domenico Delia, Istituto Nazionale Tumori, Italy) and subcloned into pcDNA4/TO/Myc-HisB and pET28a for eukaryotic and prokaryotic expression. Full-length and GzmKtruncated human importin b was amplified from human cDNAs and subcloned into pFLAG-CMV2 and pGEX-4T-1. GzmK cleavage-site mutation plasmids were generated using the Stratagene QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). pET30a-NP was kindly gifted by Dr. Xuemei Li (Institute of Biophysics), and a c-Myc sequence was inserted into the N terminus of the NP protein for immunostaining. Ran and NTF/p10 were amplified from human cDNAs and subcloned into pET30a. pCPB1, pCPB2, pCPA, pCNP, pPolINSluc, and pRLSV40 plasmids were used for luciferase assay as described previously. 16 Expression of recombinant proteins. Recombinant GzmK, mutant S-AGzmK (enzymatically inactive by mutating the active site Ser 214 to Ala
214
) were produced and purified as described previously. 10 Full-length human importin a1, tImpa1, R13A-Impa1, full-length human importin b, tImpb, Myc-NP, Ran, and NTF/p10 were expressed in Escherichia coli strain BL21 and purified through the Ni-NTA resin for 6 Â His-tagged proteins or through the GST resin for GST-tagged proteins.
Affinity chromatography. S-AGzmK was covalently coupled to 1 ml Affi-Gel 10 (Bio-Rad) resin according to the manufacturer's instructions. 1 Â 10 9 K562 cells were lysed with lysis buffer (20 mM Tris, pH 7.6, 20 mM NaCl, 0.5% NP-40, 0.5 mM EDTA, 0.5 mM EGTA, 25 mM KCl, 5 mM MgCl 2 , 1 mM PMSF, 1% protease inhibitor cocktail). The lysates were loaded and run through the S-AGzmK affinity column and then eluted through NaCl concentration gradients in 50 mM Tris-HCl, pH 7.5. The eluted fractions were resolved by SDS-PAGE and visualized by silver staining.
GzmK loading assay. K562 and HeLa cells were collected and washed three times with HBSS. Cell pellets were resuspended in loading buffer (HBSS with 0.5 mg/ml BSA, 1 mM CaCl 2 , 1 mM MgCl 2 ). Target cells (2 Â 10 5 ) in 50 ml loading buffer were incubated at 371C for the indicated lengths of time with different concentrations of GzmK plus an optimal dose of Ad as described previously. 10 Cells were incubated for an additional 15 min in 1 mM PMSF before being lysed for immunoblotting.
GzmK cleavage assay. Recombinant proteins and cell lysates (2 Â 10 5 cell equivalents) in 20 ml cleavage buffer (50 mM Tris, pH 7.6, 1 mM CaCl 2 , 1 mM MgCl 2 ) were incubated at 371C for the indicated lengths of time with different concentrations of GzmK. The reactions were stopped by addition of 5 Â SDS loading buffer, and the mixtures were then boiled for 10 min. The samples were resolved by SDS-PAGE and detected by Coomassie brilliant blue staining or immunoblotting with the indicated antibodies.
Co-immunoprecipitation assay. Recombinant proteins or cytosolic lysates (5 Â 10 6 cell equivalents in 150 ml lysis buffer, 20 mM Tris, pH 7.6, 50 mM NaCl, 1% Triton X-100, 0.1% EDTA, 0.1% EGTA) were incubated with the indicated antibodies for 2-6 h at 41C, and the immune complexes were further incubated with protein A/G beads (Santa Cruz Biotechnology) for 2 h at 41C. The immunoprecipitates were washed three times with the wash buffer (20 mM Tris, pH 7.6, 150 mM NaCl, 0.1% Triton X-100), mixed with 2 Â SDS loading buffer, and boiled for 10 min before electrophoresis. For other methods, see Supplementary Methods.
